The effects of bleomycin, mitomycin C, and cytoskeletal-disrupting drugs on angiogenesis \textit{in vitro} and haemangioma development \textit{in vivo} \\

by \\

Peaceful Mabeta \\

Submitted in partial fulfilment of the requirement for the degree \textbf{Philosophiae Doctor (Physiology)} \\
in the Faculty of Health Sciences \\
University of Pretoria \\

September 2008 \\

Supervisor: Prof MS Pepper \\
Co-supervisors: Prof NG Dippenaar \\
Dr PF Davis
Curriculum Vitae
Faculty of Health Sciences
PhD degree

Peaceful Mabeta was born in Boksburg. She obtained a BSc degree (Biochemistry and Physiology) from Medunsa. She obtained a masters degree in Physiology in 2002 from the University of Pretoria, where she currently holds a lectureship position.

Her thesis is entitled The effects of bleomycin, mitomycin C, and cytoskeletal-disrupting drugs on angiogenesis in vitro and haemangioma development in vivo. Haemangiomas are tumours of the vasculature commonly encountered in pediatrics. The treatment of these tumours has over the years remained unsatisfactory. Recently in South Africa, intralesional bleomycin therapy has been used to treat haemangiomas with promising success. However, there is very little understanding of its mechanism of action. The candidate developed a rapid and sensitive HPLC method for the measurement of bleomycin in human plasma, and demonstrated a negligible systemic spill-over of the drug following intralesional therapy in haemangioma patients. In her thesis, Ms Mabeta showed that bleomycin inhibits haemangioma growth in part by inhibiting angiogenesis. The candidate also showed that cytoskeletal-disrupting drugs with antiangiogenic activity effectively inhibit haemangioma growth in a syngeneic mouse model, thereby supporting the notion that these drugs have potential in the treatment of these tumours. Further investigation of the therapeutic potential of these drugs in the treatment of pediatric haemangiomas is underway. The examiners allocated a mark of more than 80% to the thesis.

Supervisor : Prof M.S. Pepper
Cosupervisors : Prof N.G. Dippenaar
               Dr P.F. Davis

External Examiners : Prof R. Montesano
                    Prof B. Kramer
Summary

Angiogenesis, the process of new vessel formation, appears to be a central mechanism that underlies the development of haemangiomas. Recently, intralesional bleomycin injection was used to treat paediatric haemangiomas with very good results. The purpose of this study was to determine whether there was significant systemic circulatory spill-over of bleomycin in haemangioma patients treated with intralesional bleomycin to determine safety of use. Furthermore, in order to elucidate bleomycin’s mechanism of action in inducing haemangioma regression, this study aimed at determining the effects of bleomycin on aspects of angiogenesis, namely, endothelial cell migration, growth and apoptosis, and comparing these effects with those of drugs previously reported to inhibit various aspects of the angiogenic process (mitomycin C, 2-methoxyestradiol, taxol, vincristine, vinblastine, colchicine, nocodazole and cytochalasin D). Lastly, the effects of bleomycin, mitomycin C, 2-methoxyestradiol, taxol, vincristine, vinblastine, colchicine, nocodazole and cytochalasin D were studied in an animal haemangioma model.

A rapid and highly sensitive high performance liquid chromatographic (HPLC) method was developed. Blood samples were collected from four haemangioma patients before and after (over a 24 hour period) intralesional bleomycin (IB) therapy. As a control, blood samples were also collected at identical time intervals from four patients undergoing intravenous (IV) bleomycin chemotherapy for various malignant tumours. The HPLC method was used to quantitate bleomycin fractions in patient samples. The mean bleomycin concentration detected in plasma samples obtained from IB treated patients was 0.00 µg/ml for both bleomycin A2 and B2 over the 24-hour period following therapy. Plasma bleomycin A2 and B2 levels of 360.79 and 158.85 µg/ml respectively were detected in samples obtained from cancer patients treated with bleomycin IV. These findings indicate that the low levels detected may translate to a significantly lesser risk of pulmonary fibrosis following IBI.

The effect of drugs on endothelial cell migration was analyzed by wounding a confluent monolayer of cells and determining the number of cells that had migrated from the
wound edge. Endothelial cell growth was determined in cells treated with various drug concentrations while apoptosis was examined using hematoxylin and eosin staining, DNA fragmentation assay and acridine orange staining.

The effect of test drugs on in vitro angiogenesis was determined on endothelial cells induced to form capillary-like tubes in collagen gel. Test drugs were then evaluated for antitumour activity in an animal haemangioma model.

Data demonstrated that test drugs inhibited endothelial cell migration, with the exception of mitomycin C. All test drugs induced a reduction in the percentage of viable endothelial cell in a dose-dependant manner, and also induced endothelial cell apoptosis. The drugs inhibited angiogenesis in vitro and inhibited tumour development in vivo with varying potency.

In general, results from this study indicated that there was negligible systemic spill-over of bleomycin following IB administration in patients with haemangiomas, suggesting a much lesser risk of developing bleomycin-induced pulmonary fibrosis. This study also showed that test drugs inhibited angiogenesis in vitro and haemangioma development in vivo in a mouse model. Taken together, these observations demonstrate that bleomycin may inhibit haemangioma growth by inhibiting angiogenesis. In addition, mitomycin C, 2-methoxyestradiol, taxol, vincristine, vinblastine, colchicine, nocodazole and cytochalasin D may have potential in the treatment of haemangiomas of infancy, and should be investigated further in a murine haemangioma model to determine effective dose schedules.

Keywords: bleomycin; cytoskeletal-disrupting agents; angiogenesis; haemangioma; endothelial cells; cell growth; cell migration; vascular endothelial growth factor; basic fibroblast growth factor; polyoma middle T oncogene; vascular tumour.
Angiogenese, die proses waarby nuwe bloedvate gevorm word, blyk om die sentrale mekanisme onderliggend tot die vorming van hemangiomas te wees. Onlangs is bleomisien binne-letsels ingespuit om pediatriese hemangiomas te behandel, met baie goeie resultate. Die doel van hierdie studie was om te bepaal of daar ’n noemenswaardige oorvloei van bleomisien in die sirkulatoriese stelsel van pasiënte waar daar bleomisien binne-in die letsel gespuit is, was, en om sodoende die veiligheid daarvan te kan bepaal. Verder, om die mekanisme van aksie van bleomisien op hemangioma regressie te verduidelik indien die studie ook die effekte van bleomisien op endoteelselmigrasie, groei en apoptose met betrekking tot angiogenese, met die effek van middels wat al voorheen beskryf is, vergelyk (mitomycin C, 2-methoxyestradiol, taxol, vincristine, vinblastine, cochisine, nocodazole en cytochalisin D). Ten laaste, die effekte van bogenoemde middels is ook in ’n hemangioma diere (muis) model bestudeer.

’n Vinnige en hoogs sensitiewe HPLC metode is ontwikkel. Bloed monsters is van pasiënte met hemangiomas geneem, beide voor en na (oor ’n 24 uur periode) binne-letsel inspuiting van bleomisien (IB). As kontrole, is bloedmonsters van pasiënte wat intraveneuse (IV) sistemiese bleomisien chemoterapie ontvang het vir kwaadaardige tumors, geneem. Die HPLC metode is gebruik om die vlak van bleomisien in die monsters van pasiënte te bepaal. Die gemiddelde bleomisien konsentrasie van die plasma monsters van IB behandelde pasiënte was 0.00 μg/ml bleomisien A2 en B2 onderskeidelik oor die 24 uur periode na behandeling. Plasma bleomisien A2 en B2 vlakke van 360.79 en 158.85 μg/ml onderskeidelik, is in monsters van kanker pasiënte met bleomisien IV behandel, gevind.

Die effekte van die verskillende middels op die migrasie van endoteelselle is bepaal deur ’n aaneenlopende enkellaagselle te wond en dan die aantal selle wat weg beweeg vanaf die wond te bepaal. Die groei van endoteelselle is bepaal met behulp van selle wat met verskillende konsentrasies van die middels behandel is. Apoptose is ondersoek met behulp van weefselkleuring (hematoxylin en eosin), DNA fragmenteringsbepaling en akridien oranje kleuring.

Endoteelselle wat geinduseer is om kapillêragtige buise in ’n kollageenjel te vorm, is gebruik vir die toetsing van die middels se effek op in vitro angiogenese. Die middels is dan ge-evalueer met betrekking tot die anti-tumor effek met die hemangioma muis-model.
Data het aangetoon dat die toetsmiddels endote Elviseligmigrasie onderdruk het, maar mytomycin C was
die uitsondering hier en het nie die effek gehad nie. Al die middles het ‘n afname in lewensvatbare
endote Elviselle tot gevolg gehad en die afname was afhanklik van die dosis gebruik. Almal het ook
endote Elviselapoptose veroorsaak. Die middels het \textit{in vitro} angiogenese onderdruk en het ook
tumorontwikkeling \textit{in vivo} tot ‘n meerder of minder mate onderdruk.

In die algemeen toon die resultate van hierdie studie dat daar nie ‘n noemenswaardige oorvloei van
bleomisien in pasiënte met IB behandeling vir hemangiomas was nie en kan dus hier ‘n kleiner
risiko vir die ontwikkeling van bleomisien-geinduseerde pulonêre fibrose wees.

Die studie het ook getoon dat die toetsmiddels angiogenese \textit{in vitro} onderdruk asook hemangioma
ontwikkeling in die \textit{in vivo} muis-model. Hierdie opmerkings saam dui aan dat bleomisien
hemangioma mag onderdruk deurdat angiogenese onderdruk word. Bykomstig, mitomycin C, 2-
methoxyestradiol, taxol, vincristine, vinblastine, cochisine, nocodazole and cytochalisin D kan ook
‘n potensiële rol speel by die behandeling van hemangiomas en behoort met behulp van die \textit{in vivo}
hemangioma muis-model ondersoek word om die effektiewe dosisse en skedules te bepaal.

Sleutelwoorde: bleomisien, sitoskelet-ontwrigtingsagente, angiogenese, hemangioma,
endote Elviselle, selgroei, seligmigrasie, vaskulêr endote Elvisel groeifactor, basiese fibroblast groeifactor,
poliomamiddel T onkogeen, vaskulêre tumor.
ACKNOWLEDGEMENTS

I wish to express my heart-felt appreciation to my promoter Prof Michael S. Pepper for his guidance throughout the course of this study. I have been enriched and enlightened by his advice, criticism and encouraging words (provided in just the right proportions).

I also thank my co-promoters:
Dr Paul F. Davis, in whose laboratory I learned a great deal about tissue culture, and under whose supervision the work on haemangioma biopsies was conducted. I also thank him for his input throughout the study.

Prof Nola Dippenaar for all her input and support during the HPLC work. I also thank her for all the helpful suggestions and the role she played during the editing of this thesis.

I am indebted to Dr Graham Shelver for his expert guidance with the HPLC assay method, and for his helpful suggestions and encouragement. I have been inspired by his passion for and knowledge of the HPLC system.

I thank Dr ST Tan for his role during the initial phases of this study, and for providing haemangioma patient biopsies for preliminary experiments. I appreciate his generosity and advice.

I am grateful to Prof Piet Becker (MRC Biostats Unit) for the critical role he played in assisting me to ‘make sense’ of the numbers generated from the experiments. I have also been nurtured by his warmth, insight and advice.

I thank Prof Gabriel Ionescu for making it possible for us to get all patients we needed for the study, and for coordinating and overseeing all matters pertaining to patients. I also thank Drs Muir, Semenye and Gordham who worked with Prof Ionescu to provide patient samples for this study.

I wish to express my gratitude to Prof Boomker for her advice in the editing of my thesis, and for translating the summary. Her sense of humour helped lighten-up the ‘load’.

I am deeply thankful to Thabo for being a sounding board and for his always carefully thought-out input. I thank him for his love, unwavering support and for always ‘having my back’.

I thank Bhekani, whose patience and support are unparalleled (I am truly blessed), and for being the computer ‘whiz kid’ when the compilation of this thesis required one.
I wish to express my love and gratitude to my family, especially my grandmothers Nomcqibelo (ngiyabonga Mazia for the ‘spade work’) and Mamoloko (ngwetsi ya Bataung), my Mom and my sister (Tebza) for their relentless support.

I also thank the head of the department of Physiology, Prof van Papendorp, for providing facilities and funding.

Finally I wish to acknowledge the following agencies and institutions for support:

The University of Pretoria; Navkom
Bioactivity Investigation Group and the Wellington School of Medicine
Medical Research Foundation (MRC)
National Research Foundation (NRF)
Bristol-Myers Squibb
CONTENTS

Summary .................................................................................................................... i
Opsomming ................................................................................................................ iii
Acknowledgements .................................................................................................... v
List of figures ............................................................................................................. xii
List of tables .............................................................................................................. xv

CHAPTER 1
General Introduction ................................................................................................. 1

1.1. Motivation for the study ..................................................................................... 1
1.2. Purpose of investigation .................................................................................... 2
1.3. Objectives ........................................................................................................... 3
References .................................................................................................................. 4

CHAPTER 2
Literature Review ...................................................................................................... 6

I. Bleomycin

2.1. Chemistry of bleomycin ..................................................................................... 6
2.2. Chemical structure .............................................................................................. 6
2.3. Metal ion coordination ........................................................................................ 8
2.4. Mechanism of biological activity ....................................................................... 9
  2.4.1. Effect of bleomycin on DNA ...................................................................... 9
  2.4.1. Effect of bleomycin on RNA ...................................................................... 11
  2.4.1. Effect of bleomycin on proteins .................................................................. 11
2.5. Metabolism of bleomycin ................................................................................... 11
2.6. Side Effects ......................................................................................................... 12
2.7. Clinical use ......................................................................................................... 13

II. Haemangiomas

2.8. Introduction ....................................................................................................... 13
2.9. Nomenclature ..................................................................................................... 13
2.10. Natural History ................................................................................................. 15
2.11. Complications .................................................................................................. 16
2.12. Pathophysiology ............................................................................................... 16
2.13. Treatment ........................................................................................................ 17

III. Angiogenesis concept

2.15. Growth factors in angiogenesis ...................................................................... 22
   2.15.1. Vascular endothelial growth factor ...................................................... 22
   2.15.2. Basic fibroblast growth factor .............................................................. 25

2.16. Apoptosis ....................................................................................................... 26

2.17. Mitomycin C ................................................................................................ 29

2.18. The Cell Cytoskeleton .................................................................................. 29
   2.18.1. Microfilaments ..................................................................................... 30
   2.18.2. Microtubules ........................................................................................ 31
   2.18.3. Colchicine ............................................................................................. 34
   2.18.4. 2-Methoxyestradiol .............................................................................. 34
   2.18.5. Vincristine and vinblastine .................................................................... 35
   2.18.6. Nocodazole .......................................................................................... 35
   2.18.7. Paclitaxel .............................................................................................. 35
   2.18.8. Cytochalasin D ..................................................................................... 36

References ............................................................................................................... 39

CHAPTER 3
Development of a high performance liquid chromatographic (HPLC) method for the detection of bleomycin A2 and B2 in human plasma ........................................................................................................... 49

3.1. Introduction ....................................................................................................... 49

3.2. Materials and Methods .................................................................................. 51
   3.2.1. Reagents .................................................................................................. 51
   3.2.2. Apparatus ................................................................................................ 51
   3.2.3. Preparation of mobile phase ..................................................................... 52
   3.2.4. Bleomycin stock ....................................................................................... 53
   3.2.5. Preparation of standards .......................................................................... 53
   3.2.6. Assay procedure ...................................................................................... 53
   3.2.7. Validation of the assay method ................................................................. 53
      3.2.7.1. Accuracy ............................................................................................ 53
      3.2.7.2. Linearity .......................................................................................... 53
      3.2.7.3. Specificity ........................................................................................ 53
CHAPTER 8.

Conclusion

APPENDICES

Appendix I

Appendix II

Addendum I

Addendum II

Addendum III
<table>
<thead>
<tr>
<th>Figure</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Figure 2.1</td>
<td>The chemical structure of bleomycin.</td>
<td>7</td>
</tr>
<tr>
<td>Figure 2.2</td>
<td>Proposed mechanism for the generation of activated bleomycin.</td>
<td>9</td>
</tr>
<tr>
<td>Figure 2.3</td>
<td>A model for dsDNA strand breaks.</td>
<td>10</td>
</tr>
<tr>
<td>Figure 2.4</td>
<td>Haemangioma patients treated with intralesional bleomycin.</td>
<td>19</td>
</tr>
<tr>
<td>Figure 2.5</td>
<td>Haemangioma Tissue (HT) cultured in fibrin gel.</td>
<td>20</td>
</tr>
<tr>
<td>Figure 2.6</td>
<td>Schematic diagram illustrating the process of angiogenesis.</td>
<td>21</td>
</tr>
<tr>
<td>Figure 2.7</td>
<td>Signalling pathways of vascular endothelial growth factor.</td>
<td>24</td>
</tr>
<tr>
<td>Figure 2.8</td>
<td>Schematic representation of the effects of bFGF in endothelial cells.</td>
<td>26</td>
</tr>
<tr>
<td>Figure 2.9</td>
<td>Models of cell death.</td>
<td>27</td>
</tr>
<tr>
<td>Figure 2.10</td>
<td>Apoptosis and oncosis.</td>
<td>28</td>
</tr>
<tr>
<td>Figure 2.11</td>
<td>The structure of actin.</td>
<td>30</td>
</tr>
<tr>
<td>Figure 2.12</td>
<td>Longitudinal section through a microtubule.</td>
<td>32</td>
</tr>
<tr>
<td>Figure 2.13</td>
<td>Mechanisms involved in the anti-angiogenic effects of microtubule-disrupting drugs.</td>
<td>34</td>
</tr>
<tr>
<td>Figure 3.1</td>
<td>Chromatograms.</td>
<td>56</td>
</tr>
<tr>
<td>Figure 3.2</td>
<td>Calibration curves for bleomycin A$_2$ and B$_2$ (0.1-2.0 µg/ml).</td>
<td>57</td>
</tr>
<tr>
<td>Figure 3.3</td>
<td>Calibration curves for bleomycin A$_2$ and B$_2$ (100-1000 µg/ml)</td>
<td>58</td>
</tr>
</tbody>
</table>
Figure 3.4 Chromatograms obtained from the analysis of:
A- Blenoxane; B- Blood sample obtained from: a lymphoma patient 1 hour after IV bleomycin treatment; C- Blood sample obtained from a haemangioma patient 1 hour after IB treatment.

Figure 4.1 Effect of bleomycin and mitomycin C on endothelial cell migration.

Figure 4.2 Effect of 2-methoxyestradiol and taxol on endothelial cell migration.

Figure 4.3 Effect of vincristine and vinblastine on endothelial cell migration.

Figure 4.4 Effect of colchicine and nocodazole on endothelial cell migration.

Figure 4.5 Effect of cytochalasin D on endothelial cell migration.

Figure 4.6 Effects of bleomycin and mitomycin C on HMEC-1 growth.

Figure 4.7 Effects of 2-methoxyestradiol and taxol on HMEC-1 growth.

Figure 4.8 Effects of vincristine and vinblastine on HMEC-1 growth.

Figure 4.9 Effects of colchicine and nocodazole on HMEC-1 growth.

Figure 4.10 Effects of bleomycin and mitomycin C on BME cell growth.

Figure 4.11 Effects of 2-methoxyestradiol and taxol on BME cell growth.

Figure 4.12 Effects of vincristine and vinblastine on BME cell growth.

Figure 4.13 Effects of colchicine, nocodazole and cytochalasin D on BME cell growth.

Figure 5.1 Regulation of endothelial cell apoptosis by angiogenic factors.

Figure 5.2 Photomicrographs of Hematoxylin and eosin (H&E) stained BME cells after 48 hours of exposure to bleomycin or 2-ME.

Figure 5.3 Analysis of internucleosomal fragmentation in DNA preparations following exposure of BME cells to bleomycin and mitomycin C.
Figure 5.4  Analysis of internucleosomal fragmentation in DNA preparations following exposure to cytoskeletal-disrupting drugs.

Figure 5.5  Micrographs of acridine orange stained BME cells.

Figure 6.1  Phase contrast views of the effect of bleomycin on bovine microvascular endothelial cells grown on collagen gels.

Figure 6.2  The effect of 2-methoxyestradiol (2-ME) and Taxol on BME cells grown on collagen gel

Figure 6.3  Effect of colchicine on BME cells grown on collagen gel.

Figure 6.4  Quantitative analysis of the effects of bleomycin and mitomycin C on in vitro angiogenesis.

Figure 6.5  Quantitative analysis of the effects of 2-methoxyestradiol and taxol on in vitro angiogenesis.

Figure 6.6  Quantitative analysis of the effects of vincristine and vinblastine on in vitro angiogenesis.

Figure 6.7  Quantitative analysis of the effects of colchicine, nocodazole and cytochalasin D on in vitro angiogenesis.

Figure 7.1  Schematic diagram of the experimental design.

Figure 7.2  Effects of bleomycin and mitomycin C on sEnd.2 cell growth.

Figure 7.3  Effects of 2-Methoxyestradiol and taxol on sEnd.2 cell growth.

Figure 7.4  Effects of colchicine and vinblastine on sEnd.2 cell growth.

Figure 7.5  Effects of varying doses of taxol on tumour growth in a mouse inoculated with sEnd.2 cells.

Figure 7.6  Effects of test drugs on tumour growth in mice inoculated with sEnd.2 cells.

Figure 7.7  Histology of sEnd.2 cell-induced vascular tumours in mice.

Figure 7.8  Blood parameter values in control and taxol-treated mice.

Figure 7.9  Blood parameter values in control and drug-treated mice.
LIST OF TABLE

Table 2.1 Classification of Vascular Anomalies. 15
Table 2.2 Classification of therapeutic modalities by principal mode of action. 18
Table 2.3 Receptors to the VEGF ligand and their biologic effects 23
Table 2.4 Cellular effects of cytoskeletal-disrupting agents associated with their anti-angiogenic activity. 37
Table 3.1 Summary of HPLC system and analytical conditions. 52
Table 3.2 Accuracy of the bleomycin HPLC assay method. 60
Table 3.3 Precision of the assay of BLM A2 and BLM B2 in plasma. 60
Table 3.4 Mean levels of bleomycin fractions, bleomycin A2 and B2, in plasma samples obtained over a 24hr period from haemangioma and cancer patients. 63
Table 4.1 The effects of test drugs on endothelial cell growth. 87
Table 4.2 The effects of test drugs on the growth of endothelial cells treated with 10 ng/ml basic fibroblast growth factor (bFGF). 88
Table 5.1 Test drugs induce apoptosis in BME cells. 103
Table 6.1 The effects of test drugs on in vitro angiogenesis- endothelial cells treated with 10 ng/ml basic fibroblast growth factor (bFGF). 118
Table 7.1 Drug doses from previous studies. 130
Table 7.2 Concentration values of test drugs required to inhibit sEnd.2 cell growth by 50% (IC_{50} values). 135
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANOVA</td>
<td>Analysis of variance</td>
</tr>
<tr>
<td>bFGF</td>
<td>Basic fibroblast growth factor</td>
</tr>
<tr>
<td>BLM</td>
<td>Bleomycin</td>
</tr>
<tr>
<td>BME cells</td>
<td>Bovine microvascular endothelial cells</td>
</tr>
<tr>
<td>BBCE</td>
<td>Bovine brain capillary endothelial cells</td>
</tr>
<tr>
<td>Caspaces</td>
<td>Cysteinyl aspartate-specific proteases</td>
</tr>
<tr>
<td>C18 column</td>
<td>18-Carbon reverse phase silica gel column</td>
</tr>
<tr>
<td>DdH2O</td>
<td>Deionised distilled water</td>
</tr>
<tr>
<td>MCF-7</td>
<td>Human breast carcinoma cell line</td>
</tr>
<tr>
<td>DMEM</td>
<td>Dulbecco’s modified Eagle’s medium</td>
</tr>
<tr>
<td>DMSO</td>
<td>Dimethylsulphoxide</td>
</tr>
<tr>
<td>DNA</td>
<td>Deoxyribonucleic acid</td>
</tr>
<tr>
<td>DCS</td>
<td>Donor calf serum</td>
</tr>
<tr>
<td>EC</td>
<td>Endothelial cell</td>
</tr>
<tr>
<td>ELISA</td>
<td>Enzyme-linked immunosorbent assay</td>
</tr>
<tr>
<td>FCS</td>
<td>Fetal calf serum</td>
</tr>
<tr>
<td>H&amp;E</td>
<td>Hematoxylin and Eosin stain</td>
</tr>
<tr>
<td>HPLC</td>
<td>High performance liquid chromatography</td>
</tr>
<tr>
<td>HMEC-1</td>
<td>Human microvascular endothelial cells</td>
</tr>
<tr>
<td>IC50</td>
<td>Inhibitory concentration for 50% of cells</td>
</tr>
<tr>
<td>IH</td>
<td>Infantile haemangiomas</td>
</tr>
<tr>
<td>MEM-α</td>
<td>Alpha-modified Eagle’s minimum essential medium</td>
</tr>
<tr>
<td>MMC</td>
<td>Mitomycin C</td>
</tr>
<tr>
<td>mRNA</td>
<td>Messenger RNA</td>
</tr>
<tr>
<td>NaHS</td>
<td>Sodium heptane Sulphonate</td>
</tr>
<tr>
<td>ND</td>
<td>Not detected</td>
</tr>
<tr>
<td>PBS</td>
<td>Phosphate buffered saline</td>
</tr>
<tr>
<td>RIA</td>
<td>Radioimmunoassay</td>
</tr>
<tr>
<td>RNA</td>
<td>Ribonucleic Acid</td>
</tr>
<tr>
<td>rpm</td>
<td>Revolutions per minute</td>
</tr>
<tr>
<td>rRNA</td>
<td>Ribosomal RNA</td>
</tr>
<tr>
<td>tRNA</td>
<td>Transfer RNA</td>
</tr>
<tr>
<td>UV</td>
<td>Ultra violet</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>VBL</td>
<td>Vinblastine</td>
</tr>
<tr>
<td>VCR</td>
<td>Vincristine</td>
</tr>
<tr>
<td>VEGF</td>
<td>Vascular endothelial growth factor</td>
</tr>
<tr>
<td>vWF</td>
<td>von Willebrand Factor</td>
</tr>
</tbody>
</table>